Roche's ENSPRYNG (Satralizumab) Reduces Risk of Relapses by 68% Demonstrating Potential to Become First Treatment for MOGAD
April 22, 2026
April 22, 2026
BASEL, Switzerland, April 22 (TNSxrep) -- Roche, a biotech company, issued the following news release:
* * *
Roche's ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
* Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
* MOGAD is a rare autoimmune disease of the central nervous system c . . .
* * *
Roche's ENSPRYNG (satralizumab) reduces risk of relapses by 68% demonstrating potential to become first treatment for MOGAD
* Phase III METEOROID study met its primary endpoint in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
* MOGAD is a rare autoimmune disease of the central nervous system c . . .